Two Trial Halts In A Row - Gilead Sciences Stops Late Stage COVID-19 Study
Portfolio Pulse from Vandana Singh
Gilead Sciences has halted patient enrollment in its Phase 3 BIRCH study evaluating the efficacy and safety of obeldesivir for non-hospitalized high-risk COVID-19 patients due to lower-than-expected incidence rates. This decision does not impact the OAKTREE study. Earlier, Gilead also stopped its ENHANCE-2 study in acute myeloid leukemia. GILD shares are down 0.05% at $75.51.
September 28, 2023 | 5:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Gilead's decision to halt patient enrollment in the BIRCH study and the stoppage of the ENHANCE-2 study could negatively impact investor sentiment.
The halt in patient enrollment in the BIRCH study and the stoppage of the ENHANCE-2 study could be seen as setbacks in Gilead's product pipeline, which could negatively impact investor sentiment and potentially lead to a decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100